Τίτλος:
Estrogen Receptor Expression in Pancreatic Adenocarcinoma Time to
Reconsider Evidence
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Pancreatic adenocarcinoma remains a chemotherapy-resistant and
refractory malignancy with high mortality, unaffected by recent progress
in anticancer treatment. Expression of estrogen receptors was detected
almost 50 years ago, in both benign and malignant pancreatic cells.
However, early preclinical studies in pancreatic cancer led to
contradictory findings, and most clinical studies failed to demonstrate
an effect with tamoxifen treatment. The identification of a second form
of estrogen receptor seems to provide some explanation for these
discrepancies. Predominantly expressed in malignant cells and
structurally different from what was considered the only estrogen
receptor, estrogen receptor beta was recognized as a negative prognostic
factor and a possible therapeutic target in pancreatic ductal
adenocarcinoma. Therefore, findings of research before the
identification of estrogen receptor beta should be reconsidered, and
further studies should be designed to reassess the expression and effect
of this specific estrogen receptor type in pancreatic cancer.
Συγγραφείς:
Lykoudis, Panagis M.
Contis, John
Εκδότης:
Lippincott, Williams & Wilkins
Λέξεις-κλειδιά:
pancreatic cancer; adenocarcinoma; estrogen receptor; ER-beta
DOI:
10.1097/MPA.0000000000001921
